Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Dividend Champion, Contender, And Challenger Highlights: Week Of February 8

2026-02-06
Get this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates. Read the full analysis here.

RMD Stock Up Following Q2 Earnings & Revenue Beat, Margins Expand

2026-02-06
Resmed shares rise after Q2 EPS and revenues beat expectations, with the gross and operating margins expanding sharply across core segments.

ALGN Stock Climbs on Q4 Earnings and Revenue Beat, Margins Down

2026-02-05
Align Technology shares surge after Q4 EPS and revenues beat expectations, lifted by record Clear Aligner volumes, even as gross and operating margins fall.

ResMed Deepens CPAP Lead As Wearables And Digital Tools Expand Reach

2026-02-05
ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre screening, widening its reach before patients ever enter a sleep lab. Recent FDA approvals are supporting ResMed's role in sleep and respiratory care equipment. New drug therapies are expanding the potential patient pool that may still require CPAP support. Philips' ongoing CPAP recall continues to leave ResMed with a dominant share of the CPAP market. ResMed's digital ecosystem is playing a larger role in...

The Top 5 Analyst Questions From ResMed’s Q4 Earnings Call

2026-02-05
ResMed’s fourth quarter performance drew a positive market reaction, with management attributing the outperformance to strong global demand for its masks and devices, as well as continued growth in its digital health software. CEO Michael Farrell highlighted double-digit growth in the U.S. mask segment—supported by the launch of new fabric mask products and expansion of direct-to-consumer initiatives. Management also pointed to operational efficiencies, particularly in supply chain and manufactu

Top 50 High-Quality Dividend Growth Stocks For February 2026

2026-02-04

Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions

2026-02-03
Medical device leaders counter tariff pressures with innovation, as AI adoption and aging demographics support long-term growth.

Silver Economy Boom: Investing in Healthcare's Aging Tailwinds

2026-02-03
An aging population is reshaping healthcare, with BSX, RMD, ABBV and AMGN positioned to benefit from rising senior care demand.

4 Medical Product Stocks to Watch From a Challenging Industry (Revised)

2026-02-03
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

ResMed Inc. (RMD): A Bull Case Theory

2026-02-03
We came across a bullish thesis on ResMed Inc. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc.’s share was trading at $257.61 as of January 29th. RMD’s trailing and forward P/E were 26.38 and 23.70 respectively according to Yahoo Finance. ResMed Inc. develops, manufactures, distributes, and markets […]